[HTML][HTML] The limitless future of RNA therapeutics
Recent advances in the generation, purification and cellular delivery of RNA have enabled
development of RNA-based therapeutics for a broad array of applications. RNA therapeutics …
development of RNA-based therapeutics for a broad array of applications. RNA therapeutics …
Macrophage cell membrane-based nanoparticles: a new promising biomimetic platform for targeted delivery and treatment
Y Wu, S Wan, S Yang, H Hu, C Zhang, J Lai… - Journal of …, 2022 - Springer
Synthetic nanoparticles with surface bioconjugation are promising platforms for targeted
therapy, but their simple biological functionalization is still a challenging task against the …
therapy, but their simple biological functionalization is still a challenging task against the …
Macrophage cell membrane‐cloaked nanoplatforms for biomedical applications
J Lopes, D Lopes, M Pereira‐Silva, D Peixoto… - Small …, 2022 - Wiley Online Library
Biomimetic approaches utilize natural cell membrane‐derived nanovesicles to camouflage
nanoparticles to circumvent some limitations of nanoscale materials. This emergent cell …
nanoparticles to circumvent some limitations of nanoscale materials. This emergent cell …
Recent advances in understanding the protein corona of nanoparticles and in the formulation of “stealthy” nanomaterials
In the last decades, the staggering progress in nanotechnology brought around a wide and
heterogeneous range of nanoparticle-based platforms for the diagnosis and treatment of …
heterogeneous range of nanoparticle-based platforms for the diagnosis and treatment of …
Microfluidic sonication to assemble exosome membrane-coated nanoparticles for immune evasion-mediated targeting
Using natural membranes to coat nanoparticles (NPs) provides an efficient means to reduce
the immune clearance of NPs and improve their tumor-specific targeting. However …
the immune clearance of NPs and improve their tumor-specific targeting. However …
[HTML][HTML] Nanomedicine for acute respiratory distress syndrome: the latest application, targeting strategy, and rational design
Q Qiao, X Liu, T Yang, K Cui, L Kong, C Yang… - … Pharmaceutica Sinica B, 2021 - Elsevier
Acute respiratory distress syndrome (ARDS) is characterized by the severe inflammation
and destruction of the lung air–blood barrier, leading to irreversible and substantial …
and destruction of the lung air–blood barrier, leading to irreversible and substantial …
Design of experiments in the optimization of nanoparticle-based drug delivery systems
Abstract Design of experiment (DoE) is a powerful statistical technique used for variable
screening and optimization. It is based on the simultaneous variation of multiple factors with …
screening and optimization. It is based on the simultaneous variation of multiple factors with …
[HTML][HTML] Extracellular vesicle activities regulating macrophage-and tissue-mediated injury and repair responses
Q Hu, CJ Lyon, JK Fletcher, W Tang, M Wan… - … Pharmaceutica Sinica B, 2021 - Elsevier
Macrophages are typically identified as classically activated (M1) macrophages and
alternatively activated (M2) macrophages, which respectively exhibit pro-and anti …
alternatively activated (M2) macrophages, which respectively exhibit pro-and anti …
Rapamycin-loaded biomimetic nanoparticles reverse vascular inflammation
Rationale: Through localized delivery of rapamycin via a biomimetic drug delivery system, it
is possible to reduce vascular inflammation and thus the progression of vascular disease …
is possible to reduce vascular inflammation and thus the progression of vascular disease …
[HTML][HTML] Nanotherapies for sepsis by regulating inflammatory signals and reactive oxygen and nitrogen species: New insight for treating COVID-19
L Chen, Q Huang, T Zhao, L Sui, S Wang, Z **ao… - Redox biology, 2021 - Elsevier
SARS-CoV-2 has caused up to 127 million cases of COVID-19. Approximately 5% of COVID-
19 patients develop severe illness, and approximately 40% of those with severe illness …
19 patients develop severe illness, and approximately 40% of those with severe illness …